What’s New

News
FDA allows Revalesio IND to study RNS60 in ALS
The Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application submitted by Revalesio for Phase II clinical testing of RNS60 in patients with amyotrophic lateral sclerosis (ALS)....
Read more
News
ALS ACT awards 1MM USD grant to study RNS60’s effect in a multicenter Phase II study
The ALS Association and ALS Finding a Cure® , through ALS Accelerated Therapeutic (ALS ACT), awarded a grant in the amount of 1 million US dollars to fund an investigator-initiated,...
Read more